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Abstract
Background: Efalizumab is a humanised recombinant monoclonal IgG1 antibody for the treatment
of moderate-to-severe plaque psoriasis. When treatment discontinuation is necessary, however,
some patients may experience inflammatory recurrence of the disease, which can progress to
rebound if untreated. This analysis evaluated approaches for managing inflammatory recurrence
after discontinuation of efalizumab.
Methods: An open-label, multicentre, investigational study was performed in 41 patients with
moderate-to-severe plaque psoriasis who had recently completed clinical studies with efalizumab
and had developed signs of inflammatory recurrence following abrupt cessation of treatment.
Patients were assigned by the attending physicians to receive one of five standardised alternative
systemic psoriasis treatment regimens for 12 weeks. Efficacy of the different therapy options was
assessed using the physician's global assessment (PGA) of change over time.
Results: More favourable PGA responses were observed in patients changing to cyclosporin (PGA
of 'good', 'excellent' or 'cleared': 7/10 patients, 70.0%) or methotrexate (9/20, 45.0%), compared
with those receiving systemic corticosteroids (2/8, 25.0%), retinoids (0/1, 0.0%) or combined
corticosteroids plus methotrexate (0/2, 0.0%). While the majority (77.8%) of patients showed
inflammatory morphology at baseline, following 12 weeks of the alternative therapies the overall
prevalence of inflammatory disease was decreased to 19.2%.
Conclusion: Inflammatory recurrence after discontinuation of efalizumab therapy is a manageable
event, with a number of therapies and approaches available to physicians, including short courses
of cyclosporin or methotrexate.
Background
Psoriasis is an inflammatory skin disorder that affects
approximately 2–3% of the population [1] and has a pro-
found impact on quality of life, equivalent to that of other
major diseases [2]. Patients with the disease present with
well-defined, thickened erythematous patches, typically
covered with a silver scale, and the condition is character-
ised by epidermal hyperplasia, dermal angiogenesis, infil-
tration of activated T-cells and increased cytokine levels
[3]. Chronic psoriasis is a condition requiring long-term
medication. Systemic therapies are required by patients
with moderate-to-severe disease; a variety of systemic
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therapies are available, but many of the current agents
have serious side-effects that limit long-term administra-
tion [4,5].
The aetiology and pathology of psoriasis are not well
understood, but it has been established that T-cells are
centrally involved in its development [3]. Recent under-
standing of the inflammatory pathways in psoriasis has
led to the development and use of new biologic agents to
treat the condition. One such biologic therapy, efalizu-
mab, is a humanised recombinant monoclonal IgG1 anti-
body. Efalizumab binds to the alpha-subunit, CD11a, of
the T-cell adhesion molecule, leukocyte function-associ-
ated antigen-1 (LFA-1), preventing binding with its lig-
and, intercellular adhesion molecule-1 (ICAM-1), on
target cells. This action blocks several T-cell processes
important in the pathogenesis of psoriasis, including T-
cell activation, T-cell trafficking from the circulation into
the skin, and T-cell reactivation in the dermis and epider-
mis [3,6,7].
Several large clinical studies have established the safety
and efficacy of efalizumab during extended treatment of
patients with moderate-to-severe chronic plaque psoriasis
[8-10]. There are occasions, however, such as during preg-
nancy or following vaccination or adverse events, when
patients have to stop efalizumab treatment. When treat-
ment was stopped abruptly in controlled studies, relapse
of psoriasis was reported, with exacerbation and new mor-
phology of psoriasis (see Table 1 for definitions of terms
such as 'relapse', 'rebound' and 'flare') [11]. There is cur-
rently little evidence-based medicine to guide manage-
ment and treatment of patients after discontinuation of
efalizumab. This study (protocol # IMP25180) evaluated
five regimens of standard systemic treatments for psoriasis
that have been in use for a number of years, with a view to
identifying appropriate therapy for the treatment of
'inflammatory recurrence' following discontinuation of
efalizumab. The term 'inflammatory recurrence' was used
in this study to cover two scenarios that may prompt re-
initiation of treatment in routine clinical practice: (1)
patients experience worsening of psoriasis soon after dis-
continuing treatment (within 2–3 months) that is not
considered to reflect worsening due to the natural course
of the disease, but that has not worsened sufficiently to
constitute a rebound; or (2) patients have discontinued a
psoriasis treatment due to an inflammatory disease flare
but, following discontinuation, require treatment to pre-
vent a rebound. For both these scenarios, it is important
to re-initiate treatment promptly to prevent a rebound of
psoriasis, which has been reported in approximately 5%
of patients following cessation of efalizumab treat-
ment[12] However, it should be noted that the second
scenario is very uncommon – in phase III studies of efali-
zumab only 0.6% of efalizumab-treated patients discon-
tinued treatment due to recurrence of psoriasis[13].
Table 1: Definitions of commonly-used terminology used by the US National Psoriasis Foundation (NPF), the European Medicines 
Agency (EMEA) and this study.
Term NPF [20] EMEA [21] This study
During treatment
Flare Typical or unusual worsening of disease during 
treatment and/or the occurrence of new 
psoriasis morphologies.
Not defined. Not used
Following treatment 
discontinuation
Recurrence Not defined The EMEA recommend the use of recurrence 
as an endpoint in long-terms studies provided 
that it is clearly defined.
The term 'inflammatory recurrence' includes 
(a) patients with worsening of psoriasis within 
2 months of discontinuation from efalizumab 
treatment to a level less severe than a rebound 
and (2) patients who have discontinued a 
psoriasis treatment due to an inflammatory 
disease flare but, following discontinuation, 
require treatment to prevent a rebound.
Relapse Loss of 50% of PASI improvement from 
baseline in patients who achieve a clinically 
meaningful response (≥ 50% improvement in 
PASI score from baseline).
A reduction of >50% in PASI from the achieved 
maximal improvement in PASI score.
Subjective alternative: a relapse of psoriasis 
necessitating the re-initiation of treatment.
A simple worsening of psoriasis beyond 2 
months of therapy may represent the natural 
course of the disease (relapse) rather than a 
rebound associated with drug.
Not used
Rebound A PASI of 125% of baseline or new generalized 
pustular, erythrodermic, or more 
inflammatory psoriasis occurring within 3 
months of stopping therapy.
Worsening occurring after 3 months of 
therapy may represent the natural course of 
the disease rather than a rebound associated 
with the drug.
Worsening of psoriasis over baseline value 
(e.g. PASI>125%) or new pustular, 
erythrodermic or more inflammatory psoriasis 
occurring within 2 months of stopping therapy.
A 2-month boundary separating relapse and 
rebound is drawn on theoretical grounds and 
is more or less arbitrary.
Not used
PASI, Psoriasis Area and Severity IndexBMC Dermatology 2006, 6:9 http://www.biomedcentral.com/1471-5945/6/9
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This study was intended to mimic current practice and
hence a naturalistic approach, in which the physician
chose the most appropriate therapy, was pursued. The
main objective was to provide guidance for appropriate
management of inflammatory recurrence before its pro-
gression to rebound.
Methods
This was an open-label, investigational study carried out
in nine centres on patients with moderate-to-severe
plaque psoriasis. The study was carried out according to
Good Clinical Practice guidelines and the Declaration of
Helsinki; the protocol was approved by Research Review
Board, Inc., and all patients provided signed informed
consent. Patients were enrolled in the study if: (1) they
had worsening of psoriasis within 2 months of discontin-
uation from efalizumab treatment in other studies, which
in the opinion of the investigator had not worsened suffi-
ciently to constitute a rebound but that required re-initia-
tion of treatment or, (2) had previously discontinued an
efalizumab study due to an inflammatory disease flare. To
cover both these scenarios, the term 'inflammatory recur-
rence' has been used. Patients were included if the recur-
rence was related to the disease previously treated with
efalizumab and were excluded if the recurrence was con-
sidered to be part of the natural disease progression,
which occurs more slowly (i.e. a relapse; see Table 1 for
the EMEA definition of 'relapse').
Eligible patients received 12 weeks of systemic psoriasis
therapy during the study as soon as inflammatory recur-
rence had been identified by the investigator. In order for
the study to closely reflect routine clinical practice, attend-
ing physicians were free to judge which patients had wors-
ening of disease that had not progressed to rebound and
subsequently to choose the therapy they considered most
appropriate for each individual patient from five pre-
defined regimens. Physicians could switch among these
therapies during the course of the study if it was deemed
necessary. The standard approved psoriasis therapy regi-
mens were:
￿ cyclosporin: initial dose 4.0–5.1 mg/kg/day until clini-
cal improvement (as judged by the investigator), followed
by a 50% reduction in dose every 2 weeks
￿ retinoids: initial dose 25–50 mg/day until clinical
improvement (as judged by the investigator), followed by
a 50% reduction in dose continuing for 8 weeks, at which
time therapy was stopped
￿ corticosteroids: initial dose 0.25–0.5 mg/kg/day until
clinical improvement (as judged by the investigator), fol-
lowed by a 50% reduction in dose every 2 weeks
￿ methotrexate: initial dose 20–25 mg/week until clinical
improvement (as judged by the investigator), followed by
a 25% reduction in dose every 2 weeks
￿ combined therapy: systemic corticosteroids plus meth-
otrexate, utilising both of the above regimens in combina-
tion.
The physician's global assessment (PGA) is a simple and
quick-to-use assessment of clinical status in patients with
psoriasis. The PGA is familiar to physicians and is the
standard measure of disease severity in current clinical
practice. Therefore, PGA of change was considered to be
the simplest and most appropriate measure to assess treat-
ment efficacy in the present study. PGA of change was cat-
egorised according to seven ratings: 'clear' (100%
improvement from baseline), 'excellent' (75–99%),
'good' (50–74%), 'fair' (25–49%), 'slight' (1–24%),
'unchanged' (no change in clinical signs and symptoms
from baseline) and 'worse' (deterioration of clinical signs
and symptoms from baseline). The disease was classified
according to the morphology as inflammatory, plaque,
papular/pustular, erythrodermic or inverse psoriasis and
individual patients could have more than one type. The
proportion of patients with each type was evaluated at the
start and end of treatment.
This was a pilot investigation designed to collect informa-
tion that would help plan future management strategies
for patients who experience inflammatory recurrence after
discontinuing efalizumab. There was no randomisation,
all patients were analysed as treated and no formal statis-
tical analysis was carried out. Owing to the need for treat-
ment to control psoriasis, some patients were already
allocated to one of the study drugs at the time of enrol-
ment into the study. For these patients, baseline data were
collected retrospectively, while data were collected pro-
spectively for patients who were prescribed their initial
psoriasis treatment at the time of enrolment. As the results
were qualitatively similar for the two subgroups, the
results are presented only for the two subgroups analysed
together.
Results
A total of 41 patients were enrolled in the study (24 retro-
spectively and 17 prospectively), and their demographic
details are summarised in Table 2 according to the sys-
temic treatment initially prescribed by the attending phy-
sician. The age and gender profiles were similar across
treatment groups. The systemic treatment most com-
monly prescribed was methotrexate, which was given as a
single therapy to 20 patients; this was followed by
cyclosporin, given to 10 patients, and corticosteroids,
given to eight patients. For the majority of the patients inBMC Dermatology 2006, 6:9 http://www.biomedcentral.com/1471-5945/6/9
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each treatment group, administration of one or more of
the other systemic treatments was possible.
There were five patients in total who discontinued treat-
ment before completing 12 weeks of the study. Three of
these patients were from the methotrexate group: two dis-
continued due to patient decision and one was lost to fol-
low-up; of the remaining two patients who discontinued
prematurely, one discontinued from the cyclosporin
group due to lack of efficacy, and one discontinued from
the combined methotrexate plus corticosteroid group due
to patient decision.
Assessment of PGA response
PGA for changes in disease was rated on a seven-point cat-
egorical scale from improvement resulting in clear of dis-
ease to worsening of disease. The proportions of patients
categorised as 'good', 'excellent' or 'cleared' are shown in
Table 3. The results in Table 3 are summarized according
to the initial treatment prescribed to manage inflamma-
tory recurrence (referred to as 'first treatment'), as well as
according to the treatment that the patient was receiving
at the end of the study (referred to as the 'last treatment').
This categorization of the results was designed to account
for six patients who were switched between treatments
during the study; similar results were observed when PGA
was summarised by the first or last treatment. Cyclosporin
provided the most favourable response, with a 'good',
'excellent' or 'cleared' improvement recorded for 7/10
(70.0%) patients who started on the drug. A 'good', 'excel-
lent' or 'cleared' rating was also recorded for 9/20 (45.0%)
patients who started on treatment with methotrexate.
Changes in psoriasis morphology
Psoriasis morphology at the start and end of treatment is
summarised in Table 4, according to the last treatment
prescribed. As morphology of disease was not available
for all patients, the data are shown as patients with a par-
ticular morphology as a proportion of the number of
patients with available data at baseline. For all treatment
groups combined, 21/27 (77.8%) patients with baseline
morphology data had inflammatory psoriasis at entry.
After treatment with a systemic psoriasis therapy, the prev-
alence of inflammatory disease was reduced to 19.2% of
the patients. Methotrexate appeared to provide the best
response for inflammatory psoriasis: the prevalence was
reduced from 84.6% at baseline to just 8.3% at the end of
treatment. Methotrexate also appeared to reduce the prev-
alence of papular/pustular psoriasis more than the other
treatments.
The adverse event profile associated with each of the med-
ications has been well documented, and the safety results
were consistent with the known profiles. Across all treat-
ment groups, 14 patients (34.1%) had at least one adverse
event. Adverse events were considered to be possibly or
probably related to treatment in eight patients (19.5%).
During the study, there were no deaths, serious adverse
events, or discontinuations due to adverse events.
Discussion
Efalizumab has been developed for long-term treatment
of psoriasis, and clinical studies have shown increasing
response with longer treatment duration. However, on
discontinuation of treatment there have been reports of
rebound of psoriasis symptoms, mainly in non-respond-
ing patients [11,14]. Rebound can occur with other pso-
riasis medications as was shown many years ago after
stopping systemic corticosteroids [15] as well as
cyclosporin [16,17]. If alternative therapies are instituted
immediately when inflammatory recurrence is observed,
development of rebound may be prevented. This analysis
was a preliminary exploration of appropriate alternative
therapeutic regimens for control of inflammatory disease
recurrence in patients discontinuing efalizumab, such that
progression to rebound can be avoided. As an exploratory
study, there are a number of inherent limitations that
should be accounted for when interpreting the results,
Table 2: Patient demographics at baseline, according to systemic therapy prescribed as first treatment.
Methotrexate 
(N = 20)
Cyclosporin 
(N = 10)
Corticosteroids 
(N = 8)
Combineda 
(N = 2)
Retinoids 
(N = 1)
All patients 
(N = 41)
Age (years)
Mean ± SD 49 ± 10 43 ± 12 44 ± 11 47 ± 3 41 46 ± 11
Range 28–67 20–58 20–60 45–49 - 20–67
Gender (n (%))
Male 13 (65.0) 5 (50.0) 5 (62.5) 1 (50.0) 1 (100) 25 (61.0)
Female 7 (35.0) 5 (50.0) 3 (37.5) 1 (50.0) 0 16 (39.0)
Ethnicity (n (%))
Caucasian 15 (75.0) 10 (100) 8 (100) 2 (100) 1 (100) 36 (87.8)
Asian 2 (10.0) 0 0 0 0 2 (4.9)
Other 3 (15.0) 0 0 0 0 3 (7.3)
aCombined systemic corticosteroids plus methotrexate.BMC Dermatology 2006, 6:9 http://www.biomedcentral.com/1471-5945/6/9
Page 5 of 6
(page number not for citation purposes)
including the small number of patients included in each
of the treatment groups. It should also be noted that, due
to the need for treatment to control psoriasis, some
patients were already allocated to one of the study drugs
at the time of enrolment into the study. Therefore, base-
line data were collected retrospectively for these patients.
In clinical trials, the Psoriasis Area and Severity Index
(PASI) is the most commonly used measure of disease
severity, but in a clinical setting it is difficult to use due to
its complexity. The PGA, which is more simple and quick
to use compared with the PASI is, therefore, the more
commonly used assessment in current clinical practice. In
a placebo-controlled clinical study of efalizumab for the
treatment of patients with moderate-to-severe plaque pso-
riasis, close agreement was found between the PASI and
PGA when both were used to measure improvement in
psoriasis [18]. In addition, a double-blind trial directly
compared ratings with the PASI, PGA and a National Pso-
riasis Foundation scoring system and found a strong con-
cordance between them [19]. Therefore, PGA was
considered to be the simplest and most appropriate meas-
ure for use in the present study.
The results from the present analysis indicated that meth-
otrexate and cyclosporin were effective in alleviating the
symptoms of recurrence of psoriasis. Systemic corticoster-
oids and retinoids appeared less effective in treating
inflammatory recurrence, but the small number of
patients means that further studies with these therapies
are still necessary.
Conclusion
The results from this study indicate that inflammatory
recurrence after discontinuation of efalizumab therapy is
a manageable event. In order to prevent progression to
established rebound, a number of therapies and
approaches are available to physicians, including short
courses of cyclosporin or methotrexate. Further larger-
scale studies are required to confirm the present results.
Table 3: Patients with a PGA changea of 'good', 'excellent' or 'cleared', according to first treatment (assigned at baseline) and last 
treatment (the treatment that was being received at Week 12)*.
Methotrexate Cyclosporin Corticosteroids Combinedb Retinoids All patients
First treatment (n (%)) 9/20 (45.0) 7/10 (70.0) 2/8 (25.0) 0/2 (0.0) 0/1 (0.0) 18/41 (43.9)
Last treatment (n (%)) 9/18 (50.0) 9/12 (75.0) 4/8 (50.0) 1/2 (50.0) 0/1 (0.0) 23/41 (56.1)
* At the investigators' discretion, six patients were switched between treatments during the study.
aChange from baseline.
bCombined systemic corticosteroids plus methotrexate.
PGA, physician's global assessment.
Table 4: Disease morphology at start of treatment (baseline) and at Week 12 or withdrawal (endpoint), by last treatment prescribeda.
Methotrexate (N = 13) Cyclosporine (N = 8) Corticosteroids (N = 4) Combinedb (N = 2) All patients (N = 27)
Inflammatory (n (%))
Baseline 11/13 (84.6) 6/8 (75.0) 2/4 (50.0) 2/2 (100) 21/27 (77.8)
Week 12 1/12c (8.3) 3/8 (37.5) 0/4 (0.0) 1/2 (50.0) 5/26c (19.2)
Plaque (n (%))
Baseline 7/13 (53.8) 7/8 (87.5) 4/4 (100) 2/2 (100) 23/27 (85.2)
Week 12 12/12c (100) 7/8 (87.5) 4/4 (100) 2/2 (100) 25/26c (96.2)
Papular/pustular (n (%))
Baseline 8/13 (61.5) 3/8 (37.5) 1/4 (25.0) 1/2 (50.0) 13/27 (48.1)
Week 12 2/12c (16.7) 3/8 (37.5) 0/4 (0) 1/2 (50.0) 6/26c (23.1)
Inverse (n (%))
Baseline 1/13 (7.7) 0/8 (0.0) 1/4 (25.0) 0/2 (0.0) 2/27 (7.4)
Week 12 1/12c (8.3) 0/8 (0.0) 0/4 (0.0) 0/2 (0.0) 1/26c (3.8)
Erythrodermic (n (%))
Baseline 0/13 (0.0) 1/8 (12.5) 0/4 (0.0) 0/2 (0.0) 1/27 (3.7)
Week 12 0/12c (0.0) 0/8 (0.0) 0/4 (0.0) 0/2 (0.0) 0/26c (0.0)
aValues shown are the numbers of patients with the type of morphology as a proportion of the number of patients with available data at baseline. At 
the investigators' discretion, six patients were switched between treatments during the study. No patient received retinoids at Week 12.
bCombined systemic corticosteroids plus methotrexate.
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